Drug Profile


Alternative Names: AMG 899; DEZ 001; TA-8995

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Amgen; Mitsubishi Tanabe Pharma Corporation
  • Class
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dyslipidaemias

Most Recent Events

  • 24 May 2017 AMG 899 is now called obicetrapib
  • 24 May 2017 Chemical structure information added
  • 17 Sep 2015 Dezima Pharma, Mitsubishi Tanabe Pharma and Amgen sign a patent, know-how transfer and licensing agreement for obicetrapib
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top